N-Arachidonoyl Dopamine

N-Arachidonoyl dopamine (NADA) is an arachidonoyl amino acid and cannabinoid (CB) receptor 1 agonist (K_i = 250 nM in rat brain membranes, which highly express CB₁ receptors).¹ It is selective for CB₁ over CB₂ receptors (K_i = 12,000 nM in rat spleen membranes, which highly express CB₂ receptors). NADA induces intracellular calcium mobilization in N18TG2 neuroblastoma cells (EC₅₀ = 0.7 µM). It inhibits the proliferation of MCF-7 breast cancer cells (IC₅₀ = 0.25 µM), an effect that can be reversed by the CB₁ receptor antagonist SR141716A (rimonabant; Item No. 9000484). NADA (10 mg/kg) induces hypothermia, catalepsy, hypolocomotion, and analgesia in mice.

WARNING This product is not for human or veterinary use.

1. Bisogno, T., Melck, D., Bobrov, M.Y., et al. N-acyl-dopamines: Novel synthetic CB₁ cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351(Pt 3), 817-824 (2001).

Kantae, V., Ogino, S., Noga, M., et al. Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. J. Lipid. Res. 58(3), 615-624 (2017).

Matsumoto, G., Inobe, T., Amano, T., et al. N-Acyldopamine induces aggresome formation without proteasome inhibition and enhances protein aggregation via p62/SQSTM1 expression. Sci. Rep. 8(1), 9585 (2018).